Here we show, for the first time to our knowledge, proof-of-concept results for a previously unreported therapeutic strategy using tankyrase inhibitor-mediated blockade of WNT/β-catenin signaling to counteract β-catenin-supported immune evasion and resistance to checkpoint inhibition in syngeneic murine melanoma models. The gene discussed is TNKS; the disease is melanoma.